Numerous studies have demonstrated the anticancer activity of the tomato carotenoid, lycopene. However, the molecular mechanism of this action remains unknown. Lycopene inhibition of human breast and endometrial cancer cell growth is associated with inhibition of cell cycle progression at the G 1 phase. In this study we determined the lycopene-mediated changes in the cell cycle machinery. Cells synchronized in the G 1 phase by serum deprivation were treated with lycopene or vehicle and restimulated with 5% serum. Lycopene treatment decreased serum-induced phosphorylation of the retinoblastoma protein and related pocket proteins. This eect was associated with reduced cyclin-dependent kinase (cdk4 and cdk2) activities with no alterations in CDK protein levels. Lycopene caused a decrease in cyclin D1 and D3 levels whereas cyclin E levels did not change. The CDK inhibitor p21
Introduction
Numerous epidemiological studies have demonstrated that consumption of vegetables and fruit reduces the risk of breast and other types of human cancers.
Recently, there has been a growing interest in the tomato carotenoid, lycopene, as a cancer preventive agent. Epidemiological studies have suggested that lycopene decreases the risk of several types of human malignancies, such as breast (Zhang et al., 1997) , prostate (Giovannucci et al., 1995) and lung (Michaud et al., 2000) cancer. Giovannucci reviewed data from clinical and epidemiological studies and found that most of these studies show an inverse association between tomato intake or blood lycopene level and the risk of cancer . These epidemiological data are reinforced by studies showing the inhibitory eect of lycopene on tumor cell growth in vitro (Amir et al., 1999; Countryman et al., 1991; and in vivo (Kim et al., 1997; Kobayashi et al., 1996; Nagasawa et al., 1995; Narisawa et al., 1996; Sharoni et al., 1997; .
We have previously demonstrated that lycopene inhibits the growth of mammary, endometrial, lung cancer (Levy et al., 1995) and leukemic (Amir et al., 1999) cells. This inhibition was associated with a delay in cell cycle progression from G 1 to S phase. However, data regarding its eect on cell cycle mechanisms are not available. In MCF-7 mammary cancer cells, the inhibitory eect of lycopene was more pronounced in cells partially synchronized in early G 1 phase by serum starvation followed by restimulation with serumcontaining medium, causing re-entry into the cell cycle (Karas et al., 2000) . Therefore, this model was used in the current study to investigate the molecular mechanisms involved in lycopene inhibition of G 1 phase progression in human breast (MCF-7, T-47D) and endometrial (ECC-1) cancer cells.
Recently, IGF-I has been suggested as an important risk factor for breast, prostate and colorectal cancer (Hankinson et al., 1998; Ma et al., 1999; Mantzoros et al., 1997) . Therefore, the possibility that diet components such as lycopene may decrease the risk of growth factor-related cancer warrant examination. It is welldocumented that growth factors aect the cell cycle apparatus primarily during G 1 phase, and that the main components acting as growth factor sensors are the D-type cyclins (Sherr, 1995) . Moreover, cyclin D1 is an oncogene that is overexpressed in many breast cancer cell lines as well as in primary tumors (Buckley et al., 1993) . Most interestingly, many anticancer agents, including those used for breast cancer therapy, convey their inhibitory eect in G 1 phase primarily by reducing cyclin D1 levels. These include pure antiestrogens (Watts et al., 1994) , tamoxifen (Planas Silva and Weinberg, 1997) , retinoids (Teixeira and Pratt, 1997; Zhou et al., 1997) , progestins (Musgrove et al., 1998) , as well as 1.25-dihydroxyvitamin D 3 (Wang et al., 1996) and TGF-b (Mazars et al., 1995) .
Besides their eects on cyclin D1, the above anticancer agents have been shown to exert additional eects on the cell cycle apparatus. For example, antiestrogens upregulate the CDK inhibitors p21
Cip1/Waf1 and p27
Kip1 (Watts et al., 1995) , whereas retinoic acid does not alter p27 levels but reduces p21 protein abundance (Zhou et al., 1997) . The inhibitory eect of retinoids is mediated partly by reduction in cdk2 protein levels (Teixeira and Pratt, 1997) , while antiestrogens and tamoxifen do not alter kinase protein abundance (Planas Silva and Weinberg, 1997; Watts et al., 1995) . Therefore, the aim of this study was to determine whether lycopene treatment aects the G 1 phase regulatory proteins: pocket proteins (pRb, p107 and p130), cyclins D and E, cyclin-dependent kinases (cdk4, cdk2), and CDK inhibitors, p21 and p27.
The present study is the ®rst to show that the molecular mechanism responsible for the inhibitory eect of lycopene on cell cycle in breast and endometrial cancer cells is based on reduction in cyclin D levels, and retention of p27 in cyclin E ± cdk2 complexes resulting in decreased cdk4 and cdk2 activities and inhibition of pRb phosphorylation.
Results

Lycopene inhibits cell cycle progression and cell proliferation
To assess the eect of lycopene on cell cycle progression and DNA synthesis, human breast (MCF-7 and T-47D) and endometrial (ECC-1) cancer cells were partially synchronized in the G 1 phase by serum deprivation (0.5% FCS) for 48 h with or without lycopene. This was followed by serum stimulation (5% FCS), which drove the cells from the G 1 into the S phase. As shown in Figure 1 , in serumdeprived control MCF-7, T-47D and ECC-1 cells, the S phase population was 16+2%, 3+0.5% and 4+1%, respectively.
A similar distribution was seen in the lycopenetreated cells. Serum stimulation of MCF-7, T-47D and ECC-1 control cells for 24 h resulted in about two-, four-and threefold increase in the S phase population, respectively, whereas the lycopene-treated cells showed only a minimal increase in S phase. Thus lycopene, although not completely arresting cell cycle progression, delayed G1-S transition in all cell lines tested.
In accordance with our previous data (Levy et al., 1995) Effect of lycopene on the pocket proteins: pRb, p130 and p107
Phosphorylation of pRb and its related pocket proteins, p130 and p107, is a key regulatory event during G 1 phase. Thus, our ®rst step was to determine whether their phosphorylation state was altered by lycopene action. In serum-deprived MCF-7 control cells, both the active hypophosphorylated form and the inactive hyperphosphorylated (slower migrating) forms of both pRb and p130 were present in about equal amounts ( Figure 2a ). Treatment with lycopene during serum starvation (time 0 h) resulted in a decrease in the pRb protein levels and a clear dominance of the hypophosphorylated forms of pRb and p130 (*80% of total protein). Serum addition to vehicle-treated cells, leading to re-entry of cells into the cell cycle, was accompanied by phosphorylation of pRb and p130 beginning at 6 h, and resulting in progressive accumulation of the hyperphosphorylated forms of these proteins. Pocket protein phosphorylation was markedly reduced and delayed in the lycopene-treated cells, occurring 24 h after serum addition.
The lycopene-induced reduction in pRb protein abundance, although unexplained, has been reported in studies carried out with retinoic acid (Teixeira and Pratt, 1997) , antiestrogen ICI182780 (Watts et al., 1995) , and progestins (Musgrove et al., 1998) in mammary cancer cells (MCF-7 and T-47D). The amount of the S phase-related pocket protein, p107, also decreased in the lycopene-treated MCF-7 cells despite serum stimulation (Figure 2a) .
T-47D and ECC-1 cell lines exhibited similar changes in pRb phosphorylation in response to lycopene treatment (Figure 2b) , whereas the protein level did not change. These results suggest that reduction in the pRb amount is a rather isolated eect of the carotenoid in MCF-7 cells.
Effects of lycopene on CDKs and cyclins
The decrease in pRb and p130 phosphorylation in the lycopene-treated cells is probably due to decreased CDK activity, and thus the eect of lycopene on kinase activity of the two predominant G 1 phase CDKs (cdk4 and cdk2) was characterized. Cdk4 activity was determined in cdk4 immunoprecipitates using a GST ± pRb fusion protein as a substrate. The activity measured in MCF-7 (Figure 3a) , ECC-1 and T-47D cells (data not shown) was very low in serum-starved control cells, and increased 4 ± 6 h after serum readdition, reaching peak values (®vefold increase) after 12 h. In the lycopene-treated cells, the increase in the 
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A Nahum et al cdk4 kinase activity was very low 6 h after serum readdition and its maximal level was about 40% of the control ( Figure 3a ). Cdk2 kinase activity measured in cyclin E immunoprecipitates from MCF-7, T-47D and ECC-1 cells using histone H1 as a substrate was low in serumstarved control cells, appeared 12 h following serum addition and further increased after 24 h by six-, threeand ®vefold in these cell lines, respectively ( Figure 3b ). In the lycopene-treated starved cells, this kinase activity was nearly absent and reached only 30 ± 40% of that measured in the corresponding control cells upon serum stimulation.
Lycopene-induced inhibition of serum-stimulated activity of G 1 cyclin ± kinase complexes correlated with the observed changes in pocket protein hypophosphorylation. Since this reduction in CDK activity could have resulted from changes in CDK protein levels, we then measured cdk4 and cdk2 levels in control and lycopene-treated cells. However, as shown for MCF-7 cells in Figure 3c , no such changes were detected.
Inhibition of CDK activity could also result from changes in the amount of G 1 cyclins (cyclins D and E), therefore levels of these proteins were measured. In control MCF-7 cells, serum stimulation resulted in a threefold increase in both cyclin D1 and D3 levels starting after 4 h and reaching a maximal level at 12 h for cyclin D1, and 24 h for cyclin D3 (Figure 4a ). Lycopene treatment inhibited cyclin D1 and D3 induction to a level of 40+5% as measured in the control cells.
ECC-1 cells treated with vehicle showed a ®vefold increase in cyclin D1 levels in response to serum stimulation, whereas in the lycopene-treated cells, only about a 1.5-fold increase was observed ( Figure 4a ) reaching about 20% of the maximal level measured in control cells. T-47D cells demonstrated the same trend (Figure 4a ). Another G 1 cyclin, cyclin E, displayed a small serum-induced increase in the protein level in both lycopene-treated and control MCF-7 cells, with no signi®cant dierence between the two (Figure 4b ).
Lycopene effects on CDK inhibitors, p21
CIP1 and p27
KIP1
The inhibitory eect of lycopene on cdk4 kinase activity most likely results from the observed reduction in cyclin D protein levels. However, since no change was observed in cyclin E or cdk2 protein levels we explored the possibility that inhibition of cdk2 activity was a consequence of increase in the levels of CDK inhibitors (CDKIs). p27 levels were not signi®cantly altered in response to serum stimulation in either control or lycopenetreated MCF-7 cells (Figure 4c ). In contrast, an increase in p21 levels was observed in response to serum stimulation in both lycopene-treated and nontreated cells. In control cells, p21 levels reached a maximum at 16 h followed by a decrease 24 h after serum stimulation. Interestingly, although a large serum-induced increment was detected in the lycopene-treated cells, substantially lower p21 protein levels were observed as compared with the control cells at all time points (Figure 4c) . A similar trend was found in experiments conducted with retinoic acid, where the p21 protein was induced by serum addition but to a much lesser extent than in the control cells (data not shown).
Lycopene effects on the composition of CDK-cyclin complexes
Since lycopene treatment of MCF-7 cells did not increase the total protein abundance of CDKIs, we next set out to determine whether changes in the level and ratio of inhibitors and activators in the CDKcyclin complexes could account for the inhibition of cdk2 and cdk4 kinase activity. For this purpose, these complexes were co-immunoprecipitated with antibodies against cyclin E and cyclin D1. Cyclin E complexes immunoprecipitated from control cells exhibited a time-dependent decrease in p27 content beginning at 4 h after stimulation, whereas the lycopene-treated cells retained high levels of p27 and thus exhibited a higher inhibitor to cyclin ratio in the complex ( Figure 5 ).
Levels of cdk2 were not altered signi®cantly either in the control or the lycopene treated cells. The p21 content in cyclin E complexes was higher in precipitates from control cells, and showed a biphasic response to serum stimulation similar to that seen in whole cell lysates. Cyclin D1 complexes immunoprecipitated from the serum-stimulated control cells (Figure 6 ) showed an initial increase (about twofold) in the p27 content followed by its decline after 12 h (Figure 6b ). In contrast, only a slight increase in p27 content was observed in the complexes obtained from the lycopenetreated cells (Figure 6b) . Interestingly, the protein levels of p21 in the cyclin D1 complex increased in parallel to cyclin D1 induction in control cells, whereas a much smaller induction was detected in the lycopenetreated cells (Figure 6 ).
In immunoprecipitates obtained with anti-p27 antibody (Figure 7) , the amount of the p27 both in the control and in the lycopene-treated cells did not change signi®cantly during starvation and serum stimulation, similar to the ®ndings in whole cell lysates (Figure 4c ). Cyclin D1 levels in the p27 precipitates from the control cells increased in response to serum stimulation, a phenomenon that was markedly inhibited in the lycopene-treated cells. Cyclin E levels in complexes from control cells decreased following serum stimulation, whereas lycopene treatment abolished this response (Figure 7) .
Taken together, these data further support our hypothesis that lycopene does not increase CDKI protein levels but rather aects their distribution between cyclin ± CDK complexes.
Discussion
We have recently shown that the inhibitory eect of lycopene on leukemic (Amir et al., 1999) and breast (Karas et al., 2000) cancer cells is associated with the inhibition of cell cycle progression through G 1 phase. In this study we reveal the molecular changes underlying this action in breast and endometrial cancer cells.
A major eect on the cell cycle apparatus mediated by lycopene was a reduction in cyclin D1 and D3 protein abundance. Cyclin D1 is a known oncogene (Sherr, 1996) , and an important key element in cell cycle progression. It is overexpressed in several cancer cell lines and tumors, especially breast cancer (Buckley et al., 1993; Sweeney et al., 1996) . Furthermore, overexpression of cyclin D1 mRNA has been reported to distinguish malignant from benign breast cancer tumors (Weinstat Saslow et al., 1995) . Thus reduction in cyclin D1 by lycopene treatment may contribute to its proposed action in prevention of breast and prostate cancer (Giovannucci et al., 1995; Zhang et al., 1997) .
The reduction in cyclin D1 levels by lycopene treatment may have two major consequences. The ®rst is a direct eect causing reduction in cyclin D ± cdk4 complexes resulting in a decrease in cdk4 kinase Figure 4 Lycopene eects on protein levels of G 1 cyclins and CDK inhibitors, p21 and p27. MCF-7, T-47D, and ECC-1 cells were treated as described in Figure 1 . Whole cell lysates from lycopene-treated and control cells were analysed by Western blotting for expression of: (a) cyclins D1 (MCF-7, T-47D and ECC-1), cyclin D3 (MCF-7). (b) cyclin E (MCF-7) (c) p21, p27, (MCF-7) as described under Material and methods. A representative blot from one of three experiments is shown activity. The second is probably retention of p27 in cyclin E ± cdk2 complexes, an indirect eect that leads to the inhibition of cdk2 activity. It has been suggested that it is not necessarily the total amount of inhibitors, but also their distribution between dierent complexes and the ratio of inhibitors to activators in each complex that determines CDK kinase activity (Planas Silva and Weinberg, 1997; Sherr and Roberts, 1995) . Accordingly, we hypothesized that during starvation, when the level of cyclin D ± cdk4 complexes is low, the inhibitor p27 molecules reside in both the cyclin E ± cdk2 and cyclin D ± cdk4 complexes in quantities disabling kinase activity. Following serum stimulation, as a result of an increase in the abundance of cyclin D ± cdk4 complexes, the p27 molecules are titrated by these complexes, thus lower amounts reside in the cyclin E ± cdk2 complexes. This probably relieves cdk2 from the inhibitor constraint. We have shown that this distribution of the inhibitor among CDK ± cyclin complexes is signi®cantly prevented by lycopene treatment. As a result, cdk2 complexes from the lycopene-treated cells contained larger amounts of p27 and had a higher inhibitor to cyclin ratio resulting in reduction of cdk2 activity.
The end target of CDK activation is phosphorylation of the`pocket proteins', mainly pRb. In this study, we have shown that phosphorylation of pRb and p130 is inhibited (although not abolished) by lycopene in three dierent cell lines, MCF-7, T-47D, and ECC-1. In addition the protein level of pRb is reduced in MCF-7 cells but not in the other two cell types suggesting that this reduction is probably con®ned to MCF-7 cells and is not the general rule in the action of lycopene.
Interestingly, the serum-mediated induction of p21 simultaneous to that of cyclin D1 in control cells, was markedly reduced by lycopene treatment, as found both in total cell lysate and in the cyclin ± CDK immunoprecipitates. A similar decrease in p21 abundance during inhibition of the cell cycle has been described previously in retinoids studies (Teixeira and Pratt, 1997; Zhou et al., 1997) . Several mechanisms could be responsible for this eect, such as inhibition of p53 pathways, or disruption of growth factor signals known to induce p21 protein when cells re-enter the cell cycle (Liu et al., 1996; Macleod et al., 1995) . In addition to these mechanisms, Hiyama et al. (1998) have suggested that induction of cyclin D1 is Figure 5 Lycopene eects on composition of cyclin E complexes. MCF-7 cells were treated as described in Figure 1 . Whole cell lysates from lycopene treated and control cells were subjected to immunoprecipitation with antibodies against cyclin E. (a) Immunoprecipitates were Western blotted sequentially for cyclin E, cdk2, p21 and p27. (b) Graphical presentation of the cyclin E, cdk2, p27 and p21 protein levels in the representative blot above. Levels of each protein are expressed relative to vehicle treated control cells at time 0 h accompanied by p21 induction mediated by the transcription factor E2F1. Therefore, in lycopenetreated cells, the low levels of p21 may result from inhibition of the growth factor pathway, thereby preventing cyclin D and p21 induction.
Of importance was the ®nding that the cyclin D1 ± cdk4 complexes from control cells showed an accumulation of p21 accompanying the increase in kinase activity while the complexes from lycopene-treated cells contained much lower p21 levels. This supports the suggestion that p21 promotes complex assembly and is essential for its kinase activity (Cheng et al., 1999; LaBaer et al., 1997; Zhang et al., 1994) . These data suggest the possibility that the low levels of p21 may serve as an additional inhibitory mechanism aecting cdk4 activity in lycopene-treated cells. This hypothesis is currently being studied in our laboratory.
Lycopene both resembles and diers from other anticancer agents in regard to the targeted components of the cell cycle machinery. For example, lycopene like tamoxifen, pure antiestrogens, retinoids, progestins, TGF-b and TNF-a reduces cyclin D protein abundance (Jeoung et al., 1995; Mazars et al., 1995; Planas Silva and Weinberg, 1997; Watts et al., 1995) . Whereas most of these agents have been shown to increase levels of the CDK inhibitors, p21 and p27, lycopene, like retinoic acid, reduces p21 levels. However, unlike lycopene and the above agents, retinoic acid also decreases cdk2 protein abundance (Teixeira and Pratt, 1997; Zhou et al., 1997) . These dierential eects on distinct elements of the cell cycle apparatus could produce a complementary eect on cell cycle progression, that may be the basis for a synergistic anticancer activity of lycopene and retinoic acid. Our preliminary results demonstrate such a synergistic inhibition of cell cycle progression of mammary cancer cells.
In conclusion, the data presented in this study suggest that the inhibitory eect of lycopene on cell cycle progression is mediated primarily through the down regulation of cyclin D, this action directly leads to reduction in cdk4 kinase activity. The decrease in cyclin D levels is probably related to retention of p27 in the cyclin E ± cdk2 complex resulting in inhibition of cdk2 kinase activity. The above chain of events is responsible for a decrease in pRb phosphorylation and inhibition of G 1 /S transition. The suggested molecular mechanism strengthens and complements the data accumulated from epidemiological and animal studies that demonstrated the anticancer activity of lycopene. 
Materials and methods
Lycopene puri®ed from tomato extracts (497%) was a gift from LycoRed Natural Products Industries (Beer Sheva, Israel). Tetrahydrofuran (THF), containing 0.025% butylated hydroxytoluene as an antioxidant, was purchased from SIGMA-Aldrich (Israel). Dulbecco's modi®ed Eagle's medium (DMEM), fetal calf serum (FCS), bovine insulin and Ca 2+ / Mg 2+ -free phosphate buered saline (PBS) were purchased from Biological Industries (Beth Haemek, Israel). Lycopene was dissolved in THF at a concentration of 2 mM and stored at 7208C. Immediately before the experiment, the stock solution was added to the cell culture medium, as described previously (Amir et al., 1999) . The ®nal concentration of lycopene in the medium was measured by spectrophotometer after extraction in 2-propanol and n-hexane:dichloromethane (Levy et al., 1995) . All procedures were performed under dim lighting.
Cell culture and cell proliferation assay MCF-7, human mammary cancer cell line, was purchased from American Type Culture Collection (Rockwell, MD, USA). T-47D, human mammary cancer cell line, were kindly provided by Dr Yafa Keidar (Tel-Aviv University, Israel). ECC-1 human endometrial cancer cells established and kindly provided by Dr Pondichery Satyaswaroop (Hershey Medical Center, Pennsylvania State University, USA) (Tabibzadeh et al., 1990) . Cells were grown in DMEM containing penicillin (100 U/ml), streptomycin (0.1 mg/ml), nystatin (12.5 mg/ml), insulin 0.6 mg/ml, and 5% FCS. Cells were seeded into 75-cm 2¯a sks (1.5610 6 cells) and 24-multiwell plates (35 000 cells per well) in medium containing 5% FCS. Two days later, the medium was changed to one containing 0.5% FCS and solubilized lycopene or THF alone (see above). After 48 h of serum starvation (media was replaced daily), cells were reintroduced to serum containing medium with solubilized lycopene or vehicle. THF had no eect on cell growth or the parameters measured in this study (data not shown). Cells harvested from 75 cm 2¯a sks at dierent time points were used for Western blotting, immunoprecipitation, kinase assays and¯ow cytometry assays. In parallel, cells grown in 24-multiwell plates were used for the thymidine incorporation assay. Thymidine incorporation was determined as follows: 1.25 mCi/well of [ 3 H]-thymidine (speci®c radioactivity 5 mCi/mmol) was added for 1 h. Nucleotide incorporation was stopped by adding unlabeled thymidine (0.5 mmol). The cells were then trypsinized and collected on a glass-®ber ®lter using a cell harvester (Inotech, Switzerland). Radioactivity was determined by a radioactive image analyzer (BAS 1000, Fuji, Japan).
Cell cycle analysis
Cells from 75 cm 2¯a sks were trypsinized, collected and washed twice with PBS. Cell pellets were resuspended in 200 ml PBS, ®xed in 1 ml of 70% ethanol/30% saline and stored at 7208C. Cells were washed twice with PBS followed by incubation for 40 min in 1 ml PBS containing 0.1% Triton X-100 and 30 mg of RNAse (DNAse free) at room temperature. Ten mg of propidium iodide were added and the suspension was incubated in the dark at room temperature for an additional 15 min. The suspension was then ®ltered through a 35 mm ®lter and analysed for DNA content. Flow cytometry studies were performed using the FACSCalibur¯ow cytometer (Becton Dickinson, Mountain View, CA, USA). The per cent of cells in dierent phases of the cell cycle was determined using a ModFit (Verity Software House) program.
Western blot analysis
Cells were lysed as described previously (Watts et al., 1995) with modi®cations. Cell monolayers were washed twice in ice-cold PBS and then scraped into ice-cold lysis buer A (50 mM HEPES, pH 7.5, 150 mM NaCl, 10% (v/v) glycerol, 1% (v/v) Triton X-100, 1.5 mM MgCl 2 , 1 mM EGTA, 10 mg/ ml aprotinin, 10 mg/ml leupeptin, 1 mM phenylmethylsulfonyl uoride, 2 mM sodium orthovanadate, 10 mM sodium pyrophosphate, 50 mM NaF, and 0.2 mM DTT). The lysates were incubated for 10 min on ice, and the cellular debris was cleared by centrifugation (13 000 r.p.m., 5 min, 48C). Protein content of the samples was determined by the Bradford method using a protein assay kit (Bio-Rad). Equal amounts of protein (30 ± 50 mg) were separated by SDS ± PAGE and then transferred to a PVDF membrane (Gelman, Inc.).
Proteins were visualized using the ECL detection system (Amersham) after incubation overnight at 48C with the following primary antibodies: cyclin D1 (HD-11), cyclin D3 (H-292), cyclin E (HE12), p27 (C-19), Cdk2(M2), Cdk4(C-22), p21 (C-19), p130 (C-20), p107 (C-18) from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA); or pRB (G3-245) from PharMingen (San Diego, CA, USA). Protein abundance was quantitated by densitometry analysis.
Immunoprecipitation
For cdk4 activity assays, cell monolayers were washed twice with PBS, scraped into ice-cold PBS and pelleted by centrifugation (13 000 r.p.m., 5 min). The pellets were frozen in liquid nitrogen and then resuspended in 1 ml of ice-cold lysis buer B (50 mM HEPES, pH 7.5, 150 mM NaCl, 1 mM EDTA, 2.5 mM EGTA, 0.1% (v/v) Tween 20, 10% (v/v) glycerol, 10 mM b-glycerophosphate, 1 mM NaF, 0.1 mM sodium orthovanadate, 10 mg/ml leupeptin, 10 mg/ml aprotonin, 0.2 mM DTT, and 0.1 mM phenylmethylsulfonyl¯uor-ide). The lysates were placed on ice for 60 min with intermittent vortexing and then centrifuged at 13 000 r.p.m. for 5 min at 48C. The supernatants were stored at 7708C. Cdk4 complexes were immunoprecipitated from equivalent amounts of protein with rabbit polyclonal anti-human cdk4 antibody conjugated to protein A-Sepharose (Zymed Laboratories), for 3 h at 48C. Immunoprecipitates were washed four times with ice-cold lysis buer B and three times with ice-cold 50 mM HEPES pH 7.5, 1 mM DTT. The supernatants were aspirated, and the immunoprecipitates were used for the kinase assay.
To perform the cdk2 kinase activity assay, lysates were prepared with lysis buer A as described above for Western blotting. Equivalent amounts of lysates were immunoprecipitated with anti-human cyclin E polyclonal antibody (C-19; Santa Cruz Biotechnology) conjugated to protein A-Sepharose, for 3 h at 48C. The immunoprecipitates were then washed three times with ice-cold lysis buer A, and then three times with ice-cold 50 mM HEPES, pH 7.5, 1 mM DTT.
Immunoprecipitation of cyclin D1 and cyclin E was performed as described above for cdk2 kinase activity assay, except that the antibodies were chemically cross-linked with dimethylpimilimidate (Sigma) to protein A-sepharose to reduce the background.
Eciency of imuunoprecipitation was determined by Western analysis of both the precipitate and supernatant. In all assays, three cycles of immunoprecipitation were performed yielding no immunodetectable quantities of the protein of interest in the supernatant.
Cyclin-dependent kinase assays
The kinase reactions were initiated by resuspending the immunoprecipitates in 30 ml of kinase buer (50 mM HEPES, pH 7.5, 1 mM DTT, 2.5 mM EGTA, 10 mM MgCl 2 , 20 mM ATP, 10 mCi of [g-32 P]ATP, 0.1 mM orthovanadate, 1 mM NaF, 10 mM b-glycerophosphate) containing either 2 mg of pRb (puri®ed protein 769, Santa Cruz) or 10 mg of histone H1 (Boehringer Mannheim) as a substrate. After incubation for either 30 min (cdk4), or 15 min (cdk2) at 308C, the reactions were terminated by the addition of 15 ml of 36SDS sample buer (187 mM Tris-HCl, pH 6.8, 30% (v/v) glycerol, 6% SDS, 15% (v/v) b-mercaptoethanol). The samples were then heated at 958C for 2 min and separated using 12% SDS ± PAGE. The dried gel was exposed to X-ray ®lm. Relative band intensities were quantitated by radioactive image analysis (BAS 1000, Fuji Photo Film Co., Tokyo, Japan).
